Contact
searchSearch
HMP Global
AMP Presentation

ExtraVascular Ultrasound (EVUS): A Paradigm Shift in PAD and CLI Interventions

Fadi A. Saab, MD, FACC, FSCAI, FASE 
Advanced Cardiac & Vascular Centers for Amputation Prevention, Grand Rapids, Michigan; Clinical Associate Professor of Medicine. Michigan State University College of Human Medicine, E. Lansing, Michigan

05/17/2021
Fadi Saab, MD, presents at AMP 2020. Watch/listen to this 9-minute presentation.

Subscriber

Cath Lab Digest Newsletter

Clinical & Industry News

ASC Investment
$8.8M Sale of Cardiovascular Specialty Care Center Highlights Growing Demand for Cardiovascular Surgery Centers
07/31/2026
The sale of a physician-owned cardiovascular surgery center underscores continued investment in outpatient cardiovascular care.
The sale of a physician-owned cardiovascular surgery center underscores continued investment in outpatient cardiovascular care.
The sale of a physician-owned...
07/31/2026
Cath Lab Digest
RATINGS
The Leapfrog Group Publishes Ratings for An All-Time Record Number of U.S. Hospitals and Ambulatory Surgery Centers
07/31/2026
With a record number of ASCs included, the latest Leapfrog ratings expand public reporting of ambulatory surgery center quality and safety, increasing transparency for patients and referring providers.
With a record number of ASCs included, the latest Leapfrog ratings expand public reporting of ambulatory surgery center quality and safety, increasing transparency for patients and referring providers.
With a record number of ASCs...
07/31/2026
Cath Lab Digest
Polygenic Risk Score Test
Cleerly and Allelica Partner to Launch a Polygenic Risk Score Test for Coronary Artery Disease
07/30/2026
The Cleerly Polygenic Cardiovascular Risk Score Test, powered by Allelica’s proprietary multi-ancestry PRS technology, gives physicians a new option to identify and evaluate patients with an inherited predisposition to coronary plaque.
The Cleerly Polygenic Cardiovascular Risk Score Test, powered by Allelica’s proprietary multi-ancestry PRS technology, gives physicians a new option to identify and evaluate patients with an inherited predisposition to coronary plaque.
The Cleerly Polygenic...
07/30/2026
Cath Lab Digest
CORONARY INFLAMMATION
Caristo Diagnostics’ CaRi-Heart Coronary Inflammation Technology Authorized by U.S. FDA
07/29/2026
First and only biomarker to measure coronary inflammation and assess cardiovascular mortality risk, enabling personalized disease management. CaRi-Heart Risk score identifies cardiovascular risk 10 years in advance.
First and only biomarker to measure coronary inflammation and assess cardiovascular mortality risk, enabling personalized disease management. CaRi-Heart Risk score identifies cardiovascular risk 10 years in advance.
First and only biomarker to...
07/29/2026
Cath Lab Digest
AI ECG
Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance
07/28/2026
Implicity’s newly cleared ILR ECG algorithm can now analyze data from ICMs across all major device manufacturers, including Abbott, Biotronik, Boston Scientific, and Medtronic.
Implicity’s newly cleared ILR ECG algorithm can now analyze data from ICMs across all major device manufacturers, including Abbott, Biotronik, Boston Scientific, and Medtronic.
Implicity’s newly cleared ILR...
07/28/2026
Cath Lab Digest
Meetings Update
Hot Lines Revealed – The Trials That Will Make the Headlines at ESC Congress 2026
07/23/2026
ESC Press Release Sophia Antipolis, France – 23 July 2026: The results of 59 ground-breaking trials will be unveiled for the first time at ESC Congress 2026, the annual congress of the European Society of Cardiology, which takes...
ESC Press Release Sophia Antipolis, France – 23 July 2026: The results of 59 ground-breaking trials will be unveiled for the first time at ESC Congress 2026, the annual congress of the European Society of Cardiology, which takes...
ESC Press Release Sophia...
07/23/2026
EP Lab Digest
Thrombectomy
THUNDER Study Demonstrates Penumbra’s THUNDERBOLT is Safe and Effective for Stroke Care
07/22/2026
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif....
07/22/2026
Cath Lab Digest
AI CV Prediction
CardiOmicScore: New AI Blood Test Predicts Heart Disease 15 Years Early
07/22/2026
Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have developed an artificial intelligence tool that may help predict serious cardiovascular problems many years before symptoms appear. The system, known as...
Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have developed an artificial intelligence tool that may help predict serious cardiovascular problems many years before symptoms appear. The system, known as...
Researchers at the LKS Faculty...
07/22/2026
Cath Lab Digest
Cardiogenic Shock
ACC to Launch New Cardiogenic Shock Designation to Address Deadly Gap in Heart Attack Care
07/21/2026
WASHINGTON —The American College of Cardiology (ACC) is introducing a new cardiogenic shock designation to improve outcomes for one of the most life-threatening complications of a heart attack. The new designation builds on the success of the...
WASHINGTON —The American College of Cardiology (ACC) is introducing a new cardiogenic shock designation to improve outcomes for one of the most life-threatening complications of a heart attack. The new designation builds on the success of the...
WASHINGTON —The American College...
07/21/2026
Cath Lab Digest
Stroke Interventions
Imperative Care Launches Ikon 24 Pro Guidewire, Enhancing the Zoom Stroke System to Support More Efficient Stroke Procedures
07/17/2026
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026...
07/17/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use